As of November 6, 2026, TNF Pharmaceuticals, Inc. is a publicly traded company (Nasdaq: QCLS). PharmaCyte Biotech, Inc. reports holding 74%, a majority of its shares. No bankruptcy or receivership appears in its SEC Form 8-K filings (Schedule 13D/A, November 18, 2025).
Is this your company?
About to sign with, pay or invest in TNF Pharmaceuticals, Inc.? See the free Snapshot first.
Free to see. No signup.
Is TNF Pharmaceuticals, Inc. a real, registered company?
- TNF Pharmaceuticals, Inc. files with the SEC under CIK 1321834 (its SEC filings).
- Its shares are listed under the ticker QCLS on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in New York, New York, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under TNF Pharmaceuticals, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Yossef Ehrlichman, Chief Technology Officer (Form 8-K filed 2026-09-18). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names PharmaCyte Biotech, Inc. (filed 2025-11-18).
Who are TNF Pharmaceuticals, Inc.'s owners and officers?
TNF Pharmaceuticals, Inc.: incorporated in Delaware; business address in New York, New York; industry In Vitro & In Vivo Diagnostic Substances (Form D, 2026-09-18).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer (Form D, 2025-09-05)
- : Director (Form D, 2025-09-05)
- : Executive Officer, Director (Form D, 2025-09-05)
- : Director (Form D, 2025-09-05)
- : Director (Form D, 2025-09-05)
- : Director (Form D, 2025-09-05)
- : Executive Officer, Director (Form D, 2025-09-05)
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2025-11-18 | Pharmacyte Biotech, Inc. | 74% |
Want the whole picture on TNF Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on TNF Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on TNF Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-09-18 | Yossef Ehrlichman | Chief Technology Officer | appointed |
Which insiders own TNF Pharmaceuticals, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 301,455 shares (3.7% of shares outstanding), 239,900 held directly and 61,555 indirectly (Form 4, 2026-05-14).
- , the chairman and a director: 210,845 shares (2.6% of shares outstanding) (Form 4, 2026-10-02).
- , a director: 25,024 shares (0.31% of shares outstanding) (Form 4, 2025-11-17).
- , a director: 25,000 shares (0.31% of shares outstanding) (Form 4, 2025-11-14).
- , a director: 25,000 shares (0.31% of shares outstanding) (Form 4, 2025-11-14).
Shares outstanding: 8,189,838 as of 2026-08-12, from the company's latest SEC cover page.
How much has TNF Pharmaceuticals, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2025-09-05 | $7M | $7M |
| Form D, 2024-05-31 | $26.85M | $26.85M |
| Form D, 2024-05-31 | $15.15M | $15.15M |
Keep reading
More on TNF Pharmaceuticals, Inc. and the records around it.
The people at TNF Pharmaceuticals, Inc.
- Bruce Bernstein is also named on 3 other Form D filings: XWELL, Inc. (Mar 2026), Synaptogenix, Inc. (Jun 2025)
- Joshua Silverman is also named on 1 other Form D filing: Synaptogenix, Inc. (Jun 2025)
TNF Pharmaceuticals, Inc. elsewhere on the record
- Leadership changes Sep 2026
- 5%+ stake filings Nov 2025
- Form D filing Sep 2025
Companies that share a holder
- PharmaCyte Biotech, Inc. also filed stake reports on 1 other company: FEMASYS INC (Mar 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/q-c-technologies